{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T02:46:00Z","timestamp":1791600360514,"version":"4.3.4"},"reference-count":37,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T00:00:00Z","timestamp":1684713600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Crinecerfont, a corticotropin-releasing factor type 1 receptor antagonist, has been shown to reduce elevated adrenal androgens and precursors in adults with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD), a rare autosomal recessive disorder characterized by cortisol deficiency and androgen excess due to elevated adrenocorticotropin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the safety, tolerability, and efficacy of crinecerfont in adolescents with 21OHD CAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was an open-label, phase 2 study (NCT04045145) at 4 centers in the United States. Participants were males and females, 14 to 17 years of age, with classic 21OHD CAH. Crinecerfont was administered orally (50 mg twice daily) for 14 consecutive days with morning and evening meals. The main outcomes were change from baseline to day 14 in circulating concentrations of ACTH, 17-hydroxyprogesterone (17OHP), androstenedione, and testosterone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>8 participants (3 males, 5 females) were enrolled; median age was 15 years and 88% were Caucasian\/White. After 14 days of crinecerfont, median percent reductions from baseline to day 14 were as follows: ACTH, \u221257%; 17OHP, \u221269%; and androstenedione, \u221258%. In female participants, 60% (3\/5) had \u226550% reduction from baseline in testosterone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Adolescents with classic 21OHD CAH had substantial reductions in adrenal androgens and androgen precursors after 14 days of oral crinecerfont administration. These results are consistent with a study of crinecerfont in adults with classic 21OHD CAH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1210\/clinem\/dgad270","type":"journal-article","created":{"date-parts":[[2023,5,22]],"date-time":"2023-05-22T18:05:26Z","timestamp":1684778726000},"page":"2871-2878","source":"Crossref","is-referenced-by-count":37,"title":["Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia"],"prefix":"10.1210","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6274-8530","authenticated-orcid":false,"given":"Ron S","family":"Newfield","sequence":"first","affiliation":[{"name":"Pediatric Endocrinology, University of California San Diego and Rady Children\u2019s Hospital , San Diego, CA 92123 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5741-3629","authenticated-orcid":false,"given":"Kyriakie","family":"Sarafoglou","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Endocrinology, University of Minnesota Medical School , Minneapolis, MN 55454 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1243-8304","authenticated-orcid":false,"given":"Patricia Y","family":"Fechner","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics, Division of Pediatric Endocrinology, University of Washington School of Medicine, Seattle Children\u2019s , Seattle, WA 98105 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9190-3947","authenticated-orcid":false,"given":"Natalie J","family":"Nokoff","sequence":"additional","affiliation":[{"name":"Department of Pediatric Endocrinology, University of Colorado Anschutz Medical Campus, Children\u2019s Hospital Colorado , Aurora, CO 80045 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6815-6181","authenticated-orcid":false,"given":"Richard J","family":"Auchus","sequence":"additional","affiliation":[{"name":"Departments of Pharmacology and Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School , Ann Arbor, MI 48109 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1941-8277","authenticated-orcid":false,"given":"Maria G","family":"Vogiatzi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Diabetes, The Children\u2019s Hospital of Philadelphia , Philadelphia, PA 19104 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George S","family":"Jeha","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc. , San Diego, CA 92130 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagdeep","family":"Giri","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc. , San Diego, CA 92130 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiry","family":"Roberts","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc. , San Diego, CA 92130 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Sturgeon","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc. , San Diego, CA 92130 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean L","family":"Chan","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc. , San Diego, CA 92130 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H","family":"Farber","sequence":"additional","affiliation":[{"name":"Neurocrine Biosciences, Inc. , San Diego, CA 92130 , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2023,5,22]]},"reference":[{"issue":"10108","key":"2023101816064502800_dgad270-B1","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1016\/S0140-6736(17)31431-9","article-title":"Congenital adrenal hyperplasia","volume":"390","author":"El-Maouche","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"2023101816064502800_dgad270-B2","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1210\/jc.2018-01865","article-title":"Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an endocrine society clinical practice guideline","volume":"103","author":"Speiser","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023101816064502800_dgad270-B3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MED.0000000000000308","article-title":"Growth and development in children with classic congenital adrenal hyperplasia","volume":"24","author":"Bonfig","year":"2017","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"3","key":"2023101816064502800_dgad270-B4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/MED.0b013e328346938c","article-title":"Congenital adrenal hyperplasia: an update in children","volume":"18","author":"Trapp","year":"2011","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"6","key":"2023101816064502800_dgad270-B5","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/s41574-022-00655-w","article-title":"Management challenges and therapeutic advances in congenital adrenal hyperplasia","volume":"18","author":"Mallappa","year":"2022","journal-title":"Nat Rev Endocrinol"},{"key":"2023101816064502800_dgad270-B6","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jsbmb.2015.05.013","article-title":"The next 150 years of congenital adrenal hyperplasia","volume":"153","author":"Turcu","year":"2015","journal-title":"J Steroid Biochem Mol Biol"},{"issue":"1","key":"2023101816064502800_dgad270-B7","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/EJE-21-0794","article-title":"Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia","volume":"186","author":"Prete","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2023101816064502800_dgad270-B8","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1210\/clinem\/dgab749","article-title":"Crinecerfont lowers elevated hormone markers in adults with 21-hydroxylase deficiency congenital adrenal hyperplasia","volume":"107","author":"Auchus","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023101816064502800_dgad270-B9","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2015-3574","article-title":"Single-dose study of a corticotropin-releasing factor receptor-1 antagonist in women with 21-hydroxylase deficiency","volume":"101","author":"Turcu","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2023101816064502800_dgad270-B10","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MED.0000000000000256","article-title":"Novel treatment strategies in congenital adrenal hyperplasia","volume":"23","author":"Turcu","year":"2016","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2023101816064502800_dgad270-B11","article-title":"Data from: supplementary material for \u201cCrinecerfont (NBI-74788), a CRF type 1 receptor antagonist, lowers adrenal androgens and precursors in adolescents with classic congenital adrenal hyperplasia\u201d","author":"Newfield","year":"2023","journal-title":"Mendeley Data"},{"key":"2023101816064502800_dgad270-B12","author":"Centers for Disease Control and Prevention"},{"issue":"5","key":"2023101816064502800_dgad270-B13","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/cen.13313","article-title":"Obesity in children with congenital adrenal hyperplasia in the Minnesota cohort: importance of adjusting body mass index for height-age","volume":"86","author":"Sarafoglou","year":"2017","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2023101816064502800_dgad270-B14","author":"Centers for Disease Control and Prevention"},{"issue":"10","key":"2023101816064502800_dgad270-B15","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.1210\/jc.2009-0942","article-title":"Hydrocortisone dosing during puberty in patients with classical congenital adrenal hyperplasia: an evidence-based recommendation","volume":"94","author":"Bonfig","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2023101816064502800_dgad270-B16","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1542\/peds.2005-1005","article-title":"Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"117","author":"Volkl","year":"2006","journal-title":"Pediatrics"},{"issue":"12","key":"2023101816064502800_dgad270-B17","first-page":"e5247","article-title":"Cardiovascular disease risk factors and metabolic morbidity in a longitudinal study of congenital adrenal hyperplasia","volume":"106","author":"Torky","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2023101816064502800_dgad270-B18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1590\/2359-3997000000119","article-title":"Cardiovascular risk factors and increased carotid intima-media thickness in young patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"59","author":"Rodrigues","year":"2015","journal-title":"Arch Endocrinol Metab"},{"issue":"1-2","key":"2023101816064502800_dgad270-B19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000515833","article-title":"Bone mass in young patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency","volume":"94","author":"Espinosa Reyes","year":"2021","journal-title":"Horm Res Paediatr"},{"issue":"7","key":"2023101816064502800_dgad270-B20","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1210\/jc.2013-1440","article-title":"Approach to the patient: the adult with congenital adrenal hyperplasia","volume":"98","author":"Auchus","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2023101816064502800_dgad270-B21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nrendo.2013.239","article-title":"Treatment and health outcomes in adults with congenital adrenal hyperplasia","volume":"10","author":"Han","year":"2014","journal-title":"Nat Rev Endocrinol"},{"key":"2023101816064502800_dgad270-B22","volume-title":"Corticosteroid Adverse Effects","author":"Yasir","year":"2022"},{"issue":"3","key":"2023101816064502800_dgad270-B23","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.jpeds.2014.11.027","article-title":"The relation of peripubertal and pubertal growth to final adult height in children with classic congenital adrenal hyperplasia","volume":"166","author":"Bomberg","year":"2015","journal-title":"J Pediatr"},{"issue":"5","key":"2023101816064502800_dgad270-B24","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jpeds.2014.01.011","article-title":"Impact of hydrocortisone on adult height in congenital adrenal hyperplasia-the Minnesota cohort","volume":"164","author":"Sarafoglou","year":"2014","journal-title":"J Pediatr"},{"issue":"4","key":"2023101816064502800_dgad270-B25","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(13)70138-4","article-title":"Management of adolescents with congenital adrenal hyperplasia","volume":"1","author":"Merke","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"2023101816064502800_dgad270-B26","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/bcp.14470","article-title":"An integrated PK-PD model for cortisol and the 17-hydroxyprogesterone and androstenedione biomarkers in children with congenital adrenal hyperplasia","volume":"87","author":"Al-Kofahi","year":"2021","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2023101816064502800_dgad270-B27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/JIM.0000000000000121","article-title":"Interrelationships among cortisol, 17-hydroxyprogesterone, and androstenendione exposures in the management of children with congenital adrenal hyperplasia","volume":"63","author":"Sarafoglou","year":"2015","journal-title":"J Investig Med"},{"key":"2023101816064502800_dgad270-B28","article-title":"Classic congenital adrenal hyperplasia and puberty","volume":"151","author":"Charmandari","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2023101816064502800_dgad270-B29","doi-asserted-by":"crossref","first-page":"e4666","DOI":"10.1210\/clinem\/dgab438","article-title":"Tildacerfont in adults with classic congenital adrenal hyperplasia: results from two phase 2 studies","volume":"106","author":"Sarafoglou","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2023101816064502800_dgad270-B30","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1210\/jc.2014-1258","article-title":"Abiraterone Acetate to lower androgens in women with classic 21-hydroxylase deficiency","volume":"99","author":"Auchus","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2023101816064502800_dgad270-B31","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1210\/clinem\/dgaa381","article-title":"A phase 2, multicenter study of nevanimibe for the treatment of congenital adrenal hyperplasia","volume":"105","author":"El-Maouche","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"2023101816064502800_dgad270-B32","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1043-2760(02)00670-7","article-title":"Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists","volume":"13","author":"Grammatopoulos","year":"2002","journal-title":"Trends Endocrinol Metab"},{"key":"2023101816064502800_dgad270-B33","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000262526","article-title":"Corticotropin-releasing hormone receptor antagonists: an update","volume":"17","author":"Zoumakis","year":"2010","journal-title":"Endocr Dev"},{"key":"2023101816064502800_dgad270-B34","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.psyneuen.2015.06.017","article-title":"Congenital adrenal hyperplasia and risk for psychiatric disorders in girls and women born between 1915 and 2010: a total population study","volume":"60","author":"Engberg","year":"2015","journal-title":"Psychoneuroendocrinology"},{"issue":"5","key":"2023101816064502800_dgad270-B35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1530\/EJE-10-0693","article-title":"Psychiatric characterization of children with genetic causes of hyperandrogenism","volume":"163","author":"Mueller","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2023101816064502800_dgad270-B36","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1210\/jc.2003-031322","article-title":"Endocrinologic and psychologic evaluation of 21-hydroxylase deficiency carriers and matched normal subjects: evidence for physical and\/or psychologic vulnerability to stress","volume":"89","author":"Charmandari","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2023101816064502800_dgad270-B37","doi-asserted-by":"crossref","first-page":"6079","DOI":"10.1073\/pnas.97.11.6079","article-title":"Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates","volume":"97","author":"Habib","year":"2000","journal-title":"Proc Natl Acad Sci U S A"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgad270\/50515936\/dgad270.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/11\/2871\/52218094\/dgad270.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/108\/11\/2871\/52218094\/dgad270.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T12:14:57Z","timestamp":1697631297000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/108\/11\/2871\/7175445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,22]]},"references-count":37,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,5,22]]},"published-print":{"date-parts":[[2023,10,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgad270","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,5,22]]}}}